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ABSTRACT 
Objective 
To investigate the relationship between depressive symptoms and treatment 
response and disease activity over a one-year follow-up. 
Methods 
Data from the British Society for Rheumatology Biologics Register were used, 
representing 18,421 RA patients receiving biologic treatment. Depressive symptoms 
were identified through one of three assessments: reporting a history of depression; 
the Medical Outcomes Survey 36-item Short Form (SF36); or the EuroQol (EQ5D). 
Logistic regression analyses examined the relationship between baseline depressive 
symptoms and odds of good treatment response by 1-year. Multilevel models 
addressed the association between baseline depressive symptoms and disease 
activity outcomes over 1-year follow-up, adjusting for age, gender, disease duration, 
comorbidities, and baseline disease activity and physical disability.  
Results 
Depression symptoms at biologic treatment initiation were associated with 20-40% 
reduced odds of achieving a good treatment response at 1-year. Depressive 
symptoms at baseline also associated with reduced improvement in disease activity 
over the course of follow-up. Patients with a history of depression or reporting 
symptoms of depression according to the EQ5D showed reduced improvement in 
tender and swollen joints, patient global assessment (PGA) and erythrocyte 
sedimentation rate (ESR) over 1-year follow-up. Patients with depression symptoms 
according to the SF36 showed reduced improvement in tender and swollen joints, 
but not ESR or PGA.   
Conclusion 
Experiencing symptoms of depression at the start of biologics treatment may reduce 
the odds of achieving a good treatment response, and reduce improvement in 
disease activity over time. Depression should be managed as part of routine clinical 
care to optimise treatment outcomes.  
Keywords: Rheumatoid Arthritis, Biological therapies, Depression, Epidemiology, 
Quality of life, Mental health services, Statistics 
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INTRODUCTION 
Depression is prevalent in RA, with meta-analysis evidence suggesting a 17% point 
prevalence according to diagnostic interview [1]. Recent evidence has highlighted 
depression symptoms as a prognostic psychomarker for poor rheumatological 
outcomes, with symptoms of depression and anxiety associated with worsened 
disease activity, physical function, and reduced response to Disease Modifying Anti-
Rheumatic Drug (DMARD) and glucocorticoid treatments [2,3]. Depression is rarely 
measured in rheumatological research [4]; assessment of mental health is usually 
limited to assessment of mental health domains on health-related quality-of-life 
(HRQoL) questionnaires such as the Medical Outcomes Survey 36-item Short-Form 
(SF36) [5] or the EQ5D [6].  
The development of biologic treatments for RA have revolutionised the management 
of RA; in comparison to conventional DMARDs, biologics contribute to increased 
likelihood of disease remission, and significantly improve physical function [7,8]. 
There is, however, a dearth of research examining the relationship between 
depression and long-term disease outcomes in RA [3]. The impact of comorbid 
depression on biologic treatment response has previously been investigated in a 
United States register; the authors reported an association between depressive 
symptomatology and likelihood of remission at 6-month follow-up, purported to be 
driven by an association between depression and subjective experiences of disease 
[9]. Their assessment was limited to a one-item depression comorbidity tick-box, 
which may result in high false-positive rates due to poor specificity [10]. Analysis of 
the Norwegian Disease-Modifying Anti-Rheumatic Drug (NOR-DMARD) database 
identified an association between depressive symptoms at the start of treatment with 
biological or synthetic DMARDs, and reduced risk of remission and higher pain and 
global assessment at 3- and 6- month follow-up [11]. To date, there is stronger 
evidence for a relationship between depressive symptoms and subjective 
experiences of disease such a patient global assessment (PGA) and pain [2,11–13], 
contributing to a growing focus on re-defining remission in RA [14]. 
The present study seeks to examine the longitudinal association between depressive 
symptoms and treatment response in a UK national register of RA patients starting 
their first biologic. In comparison to previous research [9], this study utilises three 
measures of depression symptoms: history of depression comorbidity tick-box, the 
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mental health domain of the SF36, and the depression/anxiety item of the EQ5D, 
providing an opportunity to investigate the differential relationships between 
depression symptoms and treatment outcomes based on mental health assessment 
strategy. The aims are: 1) to examine the relationship between baseline depression 
symptoms and biologic treatment response over 1-year follow-up; 2) to evaluate the 
relationship between baseline depression symptoms and disease activity over 1-
year. 
METHODS 
 
Participants 
This study presents an analysis of the British Society for Rheumatology Biologics 
Register for Rheumatoid Arthritis (BSRBR-RA; [15]). The BSRBR-RA is a national 
prospective register of RA patients starting a new biologic, and contains data from 
18,421 patients enrolled since its inception in 2001. To be eligible for inclusion in the 
BSRBR-RA, patients must meet UK guidelines for commencing a biologics: 
sustained active RA (defined as scoring >5.1 on the DAS28 at two timepoints a 
month apart); and failure to respond to ≥ conventional Disease modifying Anti-
Rheumatic Drugs (DMARDs) including methotrexate over a ≥6 month timeframe 
[16]. A range of clinical, demographic and psychological assessments are taken at 
baseline, 6-monthly intervals for the first 3-years of follow-up, and yearly thereafter. 
We limited our analysis to first biologic exposure only.  
Assessments 
Depression Symptoms 
Three measures of depressive symptoms are available in the BSRBR-RA database: 
upon enrolment, all patients are asked if they have ever had or received treatment 
for depression, which was used as an indicator of history of depression. The SF36 
[5] was used as an assessment of HRQoL between 2001-2008, in the first 11,937 
enrolled patients. A threshold of ≤40 on the normed mental health (nMH) subscale of 
the SF36 has been shown to have a 92.6% sensitivity and 73.2% specificity for 
identifying depression in patients with RA [17]. Responses to the SF36 were 
categorised using this threshold, to represent patients with low HRQoL. The EQ5D 
[6] was introduced to the BSRBR-RA in 2005 and became the only HRQoL 
assessment from 2010 onwards. The EQ5D has one item specific to mental health, 
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allowing patients to identify whether they are feeling “not depressed/anxious”, 
“moderately depressed/anxious”, or “extremely depressed/anxious” today. Evidence 
suggests that one-item mood screeners have 84% sensitivity and 65% specificity 
[18], and this item has been previously used to predict longitudinal DAS28 and HAQ 
outcomes, and prednisolone treatment response in RA patients [2].  
Treatment Response 
The primary outcome of interest was 1-year treatment response, measured by the 
European League Against Rheumatism (EULAR) guidelines [19]. Based on their 1-
year EULAR response, patients were categorised into those demonstrating a good 
treatment response and those with a suboptimal treatment response 
(none/moderate response). 
Disease activity 
Secondary outcomes were disease activity (measured via the DAS28), and its 
composite parts: tender joint count (TJC); swollen joint count (SJC); patient global 
assessment (PGA); and erythrocyte sedimentation rate (ESR); all measured at 1-year 
follow-up. TJC and SJC underwent square root transformation and ESR data were 
log transformed for analysis. 
Statistical Analysis 
Although data were available for three years of follow-up, only data until the first 
year of follow-up were included. This ensured a focus on first biologic exposure, 
eliminating bias introduced by patients switching biologics due to a lack of treatment 
response. All analyses were conducted on Stata v14. Clinical and demographic 
characteristics of patients having a good treatment response by 1-year were 
compared with those with no/moderate treatment response using means and 
standard deviations, with statistically significant imbalance determined using t-tests 
for continuous variables and Chi- squared tests for categorical data. 
Aim 1: The impact of baseline depressive symptoms on 1-year biologic treatment 
response 
Logistic regression models were performed in 2 stages: unadjusted (model 1), then 
adjusted for age, gender, disease duration, baseline DAS28, baseline HAQ, and 
number of comorbidities (model 2). Logistic regression estimates the odds of a 
binary outcome (i.e. having a good treatment response), based on several predictor 
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variables (i.e. baseline depression). In all models, baseline depressive 
symptomatology was entered as the predictor variable: history of depression 
(yes/no); SF36 nMH subscale (≤40/>40); EQ5D (no/moderate/extreme)). Treatment 
response at 1-year (none/moderate vs. good) was the outcome variable in primary 
analyses. Odds ratios (OR), p-values and 95% confidence intervals estimated 
whether the presence of depressive symptoms at biologic initiation was associated 
with increased odds of having a good treatment response at 1-year. Multiple 
imputation was used to address baseline missing data for DAS28, disease duration 
and HAQ.  
Aim 2: Relationship between baseline depressive symptoms and time-course 
disease activity over 1-year 
The relationships between baseline depression and 1-year DAS28, TJC, SJC, PGA 
and ESR were examined using multilevel longitudinal models, pooling data across 
the timepoints (baseline, 6-months and 1-year) [20]. Multilevel modelling handles 
hierarchically nested data, accounting for missing data, and both between- and 
within- participant variation over time, and multiple imputation was used to address 
baseline missing data for DAS28, disease duration and HAQ. 
Output from multilevel models includes unstandardized maximum likelihood 
estimates (B coefficients), which estimate the magnitude and direction of change in 
an outcome variable according to a reference group (no depressive symptoms at 
baseline). In addition to depressive symptoms as a predictor variable and DAS28 
(and its composite parts) as outcome variables, multilevel models included time as a 
continuous variable coded as 0 at baseline, 1 at 6-months and 2 at 12-months, and 
the interaction between time and baseline depressive symptoms, to examine 
whether change over time is different between people with and without symptoms of 
depression at baseline. A random intercept and random time slope allowed for 
variation in the baseline level of the outcome and the rate of change in the outcome 
between individuals. The random effects were allowed to correlate, which means 
that some control for the baseline level of the outcome is included in the model 
even though it is not included as a covariate – e.g. a positive correlation would allow 
for increasing variability in the outcome variable over time [21]. Multilevel models 
were created in two stages: 1) including only baseline depression symptoms, time 
and an interaction between time and depression symptoms, plus random effects; 
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and 2) additionally adjusting for age, gender, disease duration, comorbidities, and 
baseline physical activity (measured via the Health Assessment Questionnaire 
(HAQ) [22]). Covariates were selected based on theoretical relevance.  
RESULTS 
Missing data 
Figure 1 shows the data available for analysis for the primary outcome (treatment 
response) and secondary outcome (disease activity), in relation to the different 
methods of depressive symptom measurement. Missing response status/disease 
activity outcome data at 1-year was associated with increased BMI, and lower 
baseline DAS28, TJC, SJC, ESR and HAQ, shown in supplementary table t1. 
Baseline depression symptoms, according to all three measurements available, was 
not associated with missing outcome data.  
Participant characteristics 
Data from 18,421 patients enrolled in the BSRBR-RA by December 2015 were 
included in this analysis (figure 1). Table 1 displays baseline demographic, clinical 
and psychological variables for all patients. The mean age was 56.4 years, 76.4% 
were female, with a mean disease duration of 12.6 years and mean DAS28 of 6.4. 
By 6-months, 3,638 patients had achieved a good treatment response. At 1-year, a 
total of 5,271 (34.3%) of patients having reached a DAS28 of ≤3.2 and an 
improvement in DAS28 from baseline of >1.2. 
At 1-year follow-up, 17.9% of patients were identified as switching biologic. Biologic 
switching was significantly higher in patients reporting a history of depression, and 
depressive symptoms according to the SF36 and EQ5D at baseline (supplementary 
table t3).   
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Figure 1. Summary of the number of patients available for each outcome analysis. ^percentages calculated from the total sample. 
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Table 1.  BSRBR-RA cohort baseline characteristics for total group, and according to baseline depressive symptoms.  
  
History of depression 
 
SF36 nMH depression symptoms 
 
EQ5D depression symptoms 
 
Total Sample 
(N=18,421) 
No                    
(N=14,426; 
73.7%) 
Yes                    
(N=3,669; 
20.3%) 
p-value 
 
No                    
(N=5,388 
(45.1%)) 
Yes                    
(N=6,549, 
54.9%) 
p-value 
 
None           
(N=2,761 
(44.6%)) 
Moderate 
(N=2,975 
(48.1%)) 
Extreme                
(N=453 
(N=7.3%)) p-value 
Age, M (SD) 56.4 (12.4) 56.6 (12.6) 55.2 (11.4) <0.0001 
 
55.9 (12.1) 56.1 (12.3) 0.07 
 
57.6 (12.9) 57.1 (12.4) 54.8 (11.5) <0.0001 
Female Gender,  
N (%) 
14,065 (76.4) 10,799 (74.9) 2,999 (81.7) <0.0001 
 
4,056 (75.3) 5,057 (77.2) 0.01 
 
2,094 (75.8) 2,299 (77.3) 354 (78.2) 0.329 
BMI, M(SD) 27.3 (6.6) 27.1 (6.5) 28.1 (6.8) <0.0001 
 
26.8 (6.4) 27.0 (6.2) <0.0001 
 
27.7 (7.1) 28.2 (7.3) 29.6 (7.5) <0.0001 
Disease Duration, 
years, M(SD) 
12.6 (9.7) 12.7 (9.8) 12.3 (9.6) 0.001 
 
13.1 (9.5) 12.9 (9.7) 0.007 
 
12.1 (10.0) 11.8 (10.0) 9.8 (9.6) <0.0001 
Smoking, N(%) 
    
         Current 3,733 (20.3) 2,762 920.2) 922 (27.3) <0.0001 
 
1,053 (19.7) 1,546 (23.8) <0.0001 
 
420 (17.9) 593 (23.4) 118 (30.2) <0.0001 
Ex-smoker 6,584 (35.7) 5,176 (37.9) 1,312 (38.9) 
 
 
2,119 (39.6) 2,415 (37.1) 
  
897 (38.2) 979 (38.6) 135 (34.5) 
 Never smoked 6,990 (38.0) 5,736 (42.0) 1,141 (33.8) 
 
 
2,176 (40.7) 2,546 (39.1) 
  
1,031 (43.9) 967 (38.1) 138 (35.3) 
 Comorbidity, 
N(%)* 
9,988 (55.5) 7,565 (53.3) 2,281 (63.5) <0.0001 
 
2,747 (52.0) 3,561 (55.4) <0.0001 
     N comorbidities, 
M(SD)* 
0.9 (1.0) 0.8 (1.0) 1.1 (1.2) <0.0001 
 
0.8 (1.0) 0.9 (1.0) <0.0001 
 
0.9 (1.1) 1.0 (1.1) 1.1 (1.3) <0.0001 
Treatment Type, 
N(%)    
          Etanercept 5,356 (29.1) 4,232 (29.3) 1,039 (28.3) <0.0001 
 
1,797 (33.5) 2,275 (34.7) 0.001 
 
298 (10.8) 259 (8.7) 39 (8.6) <0.0001 
Infliximab 4,249 (23.1) 3,348 (23.2) 853 (23.3) 
 
 
1,587 (29.5) 2,062 (31.5) 
  
72 (2.6) 122 (4.1) 19 (4.2) 
 Adalimumab 5,024 (27.3) 4,044 (28.0) 904 (24.6) 
 
 
1,992 (37.0) 2,196 (33.5) 
  
840 (30.4) 993 (33.4) 162 (35.8) 
 Rituximab 1,650 (9.0) 1,208 (8.4) 393 (10.7) 
 
 
12 (0.22) 16 (0.24) 
  
654 (23.7) 813 (27.3) 100 (22.1) 
 Tocilizumab 1,008 (5.5) 709 (4.9) 267 (7.3) 
 
 
- - 
  
411 (14.9) 378 (12.7) 68 (15.0) 
 Certolizumab 1,115 (6.1) 870 (6.0) 210 (5.7) 
 
 
- - 
  
478 (17.3) 404 (13.6) 65 (14.4) 
 Infliximab 
Biosimilar 
19 (0.1) 15 (0.1) 3 (0.1) 
 
 
- - 
  
8 (0.3) 6 (0.2) 0 (0.0) 
 Baseline disease 
status     
         DAS28, M(SD) 6.4 (1.1) 6.4 (1.1) 6.4 (1.1) <0.0001 
 
6.5 (1.0) 6.6 (1.0) <0.0001 
 
5.9 (1.2) 6.1 (1.1) 6.3 (1.0) <0.0001 
TJC, M(SD) 15.2 (7.5) 15.0 (7.5) 15.9 (7.5) <0.0001 
 
15.2 (7.3) 15.9 (7.4) <0.0001 
 
13.6 (7.5) 15.0 (7.5) 16.2 (7.3) <0.0001 
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SJC, M(SD) 10.5 (6.1) 10.6 (6.1) 10.0 (6.1) 0.141 
 
11.2 (6.1) 11.5 (6.2) <0.0001 
 
8.7 (5.9) 9.0 (5.7) 9.1 (5.9) <0.0001 
PGA, M(SD) 72.0 (20.0) 71.6 (20.1) 73.6 (19.6) <0.0001 
 
70.5 (20.0) 74.2 (19.3) <0.0001 
 
68.5 (21.0) 72.5 (18.8) 79.1 (18.5) <0.0001 
ESR, M(SD) 43.2 (28.4) 47.0 (29.1) 35.9 (25.1) <0.0001 
 
45.2 (12.1) 46.5 (28.6) <0.0001 
 
36.0 (26.9) 37.8 (27.6) 38.8 (29.0) <0.0001 
HAQ, M(SD) 1.9 (0.6) 1.9 (0.6) 2.1 (0.6) <0.0001 
 
1.9 (0.6) 2.1 (0.6) <0.0001 
 
1.5 (0.7) 1.9 (0.6) 2.2 (0.5) <0.0001 
RF+, N(%) 11,275 (64.3) 8,985 (64.1) 2,113 (62.1) 0.002 
 
3,465 (64.4) 4,267 (65.2) 0.324 
 
1,484 (61.5) 1,669 (62.5) 255 (63.9) 0.58 
Good 1-year 
treatment 
response, N(%)* 5,271 (34.3) 4,293 (35.5) 917 (30.0) <0.0001   1,665 (34.7) 1,759 (30.1) <0.0001   997 (44.7) 856 (34.9) 97 (26.4) <0.0001 
*data available for 15,386 participants.  
 
 
 
 
 
 
 
 
 
 
Table 2. Association between baseline depression and treatment response at 12-months. 
  
History of depression  
 
SF36 (nMH≤40) 
 
EQ5D  
    OR 95%CI p 
 
OR 95%CI p 
 
OR 95%CI p 
Unadjusted Depression symptoms (vs. none) 0.75 0.66, 0.85 <0.0001 
 
0.79 0.69, 0.92 0.002 
 
- - - 
 
Moderate depression symptoms (vs. none) - - - 
 
- - - 
 
0.76 0.63, 0.91 0.003 
 
Extreme depression symptoms (vs. none) - - - 
 
- - - 
 
0.51 0.38, 0.69 <0.0001 
Adjusted* Depression symptoms (vs. no depression) 0.80 0.69, 0.92 0.002 
 
0.90 0.77, 1.18 0.177 
 
- - - 
 
Moderate depression symptoms (vs. none) - - - 
 
- - - 
 
0.85 0.69, 1.04  0.105 
  Extreme depression symptoms (vs. none) - - -   - - -   0.62 0.45, 0.87 0.005 
* adjusted for age, gender, disease duration, baseline DAS28, number of comorbidities, baseline HAQ. SF36 Medical Outcomes Survey 36-item Short Form. nMH normed Mental Health 
subscale. OR odds ratio. CI confidence interval. N Number of participants included in analysis.  
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History of depression 
In comparison to patients without a history of depression, logistic regression 
indicated that patients reporting a history of depression have reduced odds 
(OR=0.80, 95%CI: 0.69-0.92) of having a good treatment response by 1-year 
follow-up after adjusting for covariates (table 2).  
Using multilevel longitudinal models, patients reporting a history of depression 
reported significantly lower levels of baseline DAS28 (B=-0.07, 95%CI:-0.12, -0.02) 
but a significantly lower rate of improvement in DAS28 over time in comparison to 
patients without a history  of depression (table 3). Those without a history of 
depression reported a total improvement in DAS28 of -0.4 at 1-year, whereas. 
patients with a history of depression reported a decrease in DAS28 score of -0.36 
between baseline and 1-year follow-up (table 3). This significant interaction effect is 
displayed graphically in figure 2.  
Supplementary tables t3-t6 show the results of the multilevel longitudinal analyses 
examining the relationship between history of depression status and TJC, SJC, 
PGA and ESR outcomes respectively. Patients without a history of depression show 
significantly reduced improvement in all components over time in comparison to 
patients with a history of depression.   
 
SF36 nMH subscale 
In comparison to patients scoring ≤40 on the SF36 nMH subscale, logistic 
regression analysis revealed that those scoring >40, had no significant difference in 
the odds of having a good treatment response at one-year follow-up (table 2).  
According to multilevel longitudinal analysis, there were no differences in baseline 
DAS28 levels between those scoring ≤40 and >40 on the nMH subscale, although 
patients scoring ≤40 reported a significantly reduced rate of improvement in DAS28 
over time in comparison to those scoring >40. Whereas patients scoring >40 on the 
nMH reduce in DAS28 scores by -0.42 at 1-year, patients scoring ≤40 show an 
overall improvement in DAS28 of -0.40 by one-year follow-up (table 3). This 
significant interaction effect is shown graphically in figure 2. 
Supplementary tables t3-t6 show the results of the multilevel analyses examining 
the relationship between nMH status and TJC, SJC, PGA and ESR outcomes 
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respectively. Depressive symptomatology according to the SF36 nMH subscale was 
not associated with change in PGA or ESR scores over time, however patients 
scoring ≤40 showed reduced improvements in TJC and SJC outcomes in 
comparison to patients scoring >40. 
 
EQ5D 
Logistic regression analysis adjusting for covariates, reveals no significant 
difference in odds of having a good treatment response between patients reporting 
no depression symptoms and those reported moderate symptoms (OR=0.85, 
95%CI: 0.69-1.04). In comparison to patients reporting no depression symptoms, 
those reporting extreme depression symptoms had a significantly reduced odds of a 
good treatment response at 1-year follow-up (OR=0.62, 95%CI: 0.45-0.87) (table 
2).   
Results of longitudinal multilevel analyses reveal no significant difference between 
depression symptom groups and baseline levels of DAS28, however in comparison 
to patients with no depression symptoms at baseline, those with moderate and 
extreme symptoms show significantly reduced rate of improvement over time. In 
comparison to patients with no symptoms of depression according to the EQ5D, 
who improve by -0.38 at 1-year follow-up, patients with some symptoms and 
extreme symptoms report reductions in DAS28 of -0.34 and -0.32 respectively at 
one-year follow-up (table 3). The significant interaction between depression 
symptoms and follow-up timepoint is displayed graphically in figure 2.  
Supplementary tables t3-t6 show the results of the multilevel analyses examining the 
relationship between EQ5D status and TJC, SJC, PGA and ESR outcomes 
respectively. In comparison to patients with no symptoms of depression at baseline, 
those with moderate symptoms show significantly reduced improvements in TJC, 
SJC, PGA and ESR over time. In comparison to patients with no symptoms of 
depression at baseline, those with extreme symptoms show significantly reduced 
improvements in TJC, SJC and ESR over time. 
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Table 3.Association between baseline depression, and DAS28 outcomes over 12-month follow-up. 
 
History of depression   SF36 (nMH ≤40)   EQ5D 
 
B 95%CI p   B 95%CI p   B 95%CI p 
Unadjusted 
           Depression symptoms (vs. none) 0.03 -0.02, 0.08 0.294 
 
0.14 0.09, 0.19 <0.0001 
 
- - - 
Moderate depression symptoms (vs. none) - - - 
 
- - - 
 
0.25 0.18, 0.32 <0.0001 
Extreme depression symptoms (vs. none) - - - 
 
- - - 
 
0.50 0.36, 0.64 <0.0001 
Follow-up number -0.20 -0.21, -0.20 <0.0001 
 
-0.21 -0.21, -0.20 <0.0001 
 
-0.19 -0.20, -0.18 <0.0001 
Depression*follow-up 0.02 0.02, 0.03 <0.0001 
 
0.01 0.00, 0.01 0.003 
 
- - - 
Moderate depression (vs. none) - - - 
 
- - - 
 
0.02 0.01, 0.03 <0.0001 
Extreme depression (vs. none) - - -   - - -   0.03 0.01, 0.05 <0.0001 
Adjusted^ 
           Depression symptoms (vs. none) -0.07 -0.12, -0.02 0.011 
 
0.03 -0.02, 0.08 0.276 
 
- - - 
Moderate depression symptoms (vs. none) - - - 
 
- - - 
 
0.04 -0.04, 0.11 0.364 
Extreme depression symptoms (vs. none) - - - 
 
- - - 
 
0.11 -0.04, 0.26 0.144 
Follow-up number -0.20 -0.21, -0.20 <0.0001 
 
-0.21 -0.21, -0.20 <0.0001 
 
-0.19 -0.20, -0.19 <0.0001 
Depression symptoms*follow-up 0.02 0.02, 0.03 <0.0001 
 
0.01 0.00, 0.01 0.002 
    Moderate depression symptoms (vs. none) - - - 
 
- - - 
 
0.02 0.01, 0.03 <0.0001 
Extreme depression symptoms (vs. none) - - -   - - -   0.03 0.01, 0.05 0.001 
^model adjusted for age, gender, disease duration, comorbidities and baseline HAQ. B unstandardized coefficient. 
SF36 Medical Outcomes Survey 36-item Short Form. nMH normed Mental Health subscale.  
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Figure 2. Graphical representation of fully-adjusted interactions between baseline depression 
symptoms and time on DAS28 outcomes over 12-month follow-up. 
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DISCUSSION 
This study found symptoms of depression at baseline to be associated with reduced 
long-term odds of reaching clinical remission in patients receiving their first biologic 
drug. This supports previous evidence from US and Norwegian demonstrating 
reduced likelihood of reaching remission in patients with symptoms of depression at 
treatment initiation [9,11]. We also identified prospective associations between 
baseline depression symptom status and disease activity, with depression 
symptoms contributing to increased DAS28 over the 12-month follow-up, and 
impacting change in DAS28 in response to treatment. Examination of the DAS28 
components identified associations between depression and both subjective and 
objective aspects of disease activity; effect sizes did not differ between subjective 
and objective outcomes, contradicting previous research findings emphasising the 
relationship between depressive symptoms and subjective experiences of disease 
[3,11,23].  
There are several explanations for this novel finding. Firstly, depression is known to 
impact health behaviours such as medication adherence [24], and non-adherence 
to biologics has been shown to reduce DAS28 treatment response [25]. Whilst 
adherence data is not collected for all contributors to the BSRBR-RA databset and 
not available for inclusion in this paper, the role of adherence as a mechanism for 
this relationship is a valuable area for future research. Secondly, there may be a 
biological explanation for these findings. Systemic inflammation and elevated 
cytokines typically associated with RA disease manifestation and disease severity 
are also identified in people with depressive disorder [26–28]. Finally, the large 
sample size available for this analysis may have provided sufficient statistical power 
to identify small effect sizes typically unobservable in smaller datasets.  
We identified differential effects of symptoms of depression symptoms on 
rheumatological outcomes, based on the depression assessment method. Whereas 
a history of depression and EQ5D categories were largely predictive of all assessed 
outcomes, either showing a main effect or modifying change over time, the SF36 
was not associated with ESR or PGA. This may be due to these assessments 
representing different elements of mental health. Ticking a depression comorbidity 
tick box may indicate a lifetime history of depression, or exposure to mental health 
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treatment, however it provides no timeframe or qualifications for endorsement [29]. 
As the history of depression assessment may include people who have previously 
received treatment for depression, they may not be experiencing current 
symptomatology. This measure should be viewed as lifetime depression 
prevalence, rather than presence of current symptomatology. 
The SF36, alternatively, contains multiple items covering a range of psychological 
symptoms, including happiness, nervousness, calmness, tiredness and participation 
in social activities [5] and is framed to detect a change from normality within the last 
month. It may represent a more nuanced perspective of mental health, including 
positive and negative affect, as well as psychosomatic and behavioural symptoms 
often associated with chronic illness. We used thresholds based on a validation 
study [30], but the high prevalence of “depression” measured on the SF-36 
suggests a lack of specificity which may have reduced effect sizes due to 
measurement error [31].  The EQ5D assesses current depressive symptomatology, 
and although by no means a diagnostic test for depression, representing moderate 
sensitivity and specificity, the low proportion of patients reporting “extreme 
depression/anxiety” is lower than typical prevalence estimates of depression in RA 
[1]. 
This study has used appropriate longitudinal data analysis methodology to examine 
the long-term relationship between symptoms of depression and biologic treatment 
response. There is a shortage of high-quality longitudinal investigation in this field, 
and the evidence that does exist is limited to studies with highly selected samples, 
suboptimal depression assessments, inadequate adjustment for confounding 
variables, and inappropriate analysis methodologies [3]. The current study uses the 
largest prospective observational biologics registry in the world to examine the 
impact of depression symptoms on outcomes in real-world patients undergoing 
biologic treatment. Our results are therefore externally valid, representing patients 
prescribed biologics across the UK; a diverse population. 
There are limitations to consider when interpreting these findings. Although 
providing several interpretations of depression, none of the measurement tools 
available for baseline depression are “gold-standard” indicators of the presence of 
diagnostically ascertained depression. Due to the scarcity with which validated 
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screening tools or diagnostic interviews are utilised to measure depression in RA 
research [4], the opportunity to compare three methods in the current paper is 
helpful, however given the high prevalence and impact of depression on disease 
outcomes, symptoms of depression should be routinely measured in 
rheumatological practice.  
We did not adjust our models for treatment type, or previous failure with 
conventional DMARDs. As all patients are receiving biologics and there is no well-
established association between different types of biologic or DMARD on our 
dependent or independent variables, we chose not to include treatment type as a 
confounder in our models. No data were available on concurrent mental health 
treatment, and it is likely that some patients may have been receiving therapy or 
antidepressant treatments which may reduce our observed effects.  
These results contribute to the growing body of literature highlighting the role 
depression plays in predicting long-term health outcomes and treatment response in 
RA. These findings have several implications. Repeated screening and 
management of mental disorder should be undertaken as part of clinical care. 
Biologics are expensive [32], and poor treatment response can result in switching 
biologics, which can result in further costs [33]. Depression should therefore be 
routinely measured in RA clinical trials, and in clinical practice.  
In conclusion, experiencing symptoms of depression at the start of biologics 
treatment is associated with reduced treatment response, impacting change over 
time in disease activity. The management of symptoms of depression in routine 
care is NICE recommended [34], and depression is treatable within the context of 
long-term physical health conditions [35–37]. Future research examining the impact 
of mental health intervention for physical health outcomes may identify whether 
effectively managing depression can improve treatment response in RA.  
Key Messages 
1. Depression at baseline contributes to approximately 30% reduced odds of 
good biologics treatment response.   
2. Depression is associated with reduced change in DAS28 over time in 
response to biologics. 
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